The FDA's April 2026 withdrawal of BPC-157 from Category 2 removed an explicit enforcement restriction but left the peptide without authorization for routine 503A compounding, as it is neither an approved drug nor on the official bulks list. In July 2026 the Pharmacy Compounding Advisory Committee voted 8-6 (one abstention) to recommend adding BPC-157 (free base and acetate) to the 503A Bulk Drug Substances List for ulcerative colitis use, despite FDA staff briefing documents citing insufficient human safety and efficacy data and potential immunogenicity risks. This non-binding advisory step does not confer Category 1 status or enforcement discretion; any change requires formal notice-and-comment rulemaking, a process that typically spans eight to twenty-four months. No subsequent FDA action or interim Category 1 placement has been reported as of early September 2026.
Polymarket ডেটা রেফারেন্স করে পরীক্ষামূলক AI-জেনারেটেড সারাংশ। এটি ট্রেডিং পরামর্শ নয় এবং এই মার্কেট কীভাবে রেজলভ হয় তাতে কোনো ভূমিকা রাখে না। · আপডেটেডনতুন
Dec 31, 2026
December 31, 2026
51%
$4,143 Vol.
December 31, 2026
$2,141 Vol.
51%
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.The FDA's April 2026 withdrawal of BPC-157 from Category 2 removed an explicit enforcement restriction but left the peptide without authorization for routine 503A compounding, as it is neither an approved drug nor on the official bulks list. In July 2026 the Pharmacy Compounding Advisory Committee voted 8-6 (one abstention) to recommend adding BPC-157 (free base and acetate) to the 503A Bulk Drug Substances List for ulcerative colitis use, despite FDA staff briefing documents citing insufficient human safety and efficacy data and potential immunogenicity risks. This non-binding advisory step does not confer Category 1 status or enforcement discretion; any change requires formal notice-and-comment rulemaking, a process that typically spans eight to twenty-four months. No subsequent FDA action or interim Category 1 placement has been reported as of early September 2026.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
মার্কেট ওপেন হয়েছে: Jun 22, 2026, 10:10 PM ET
ভলিউম
$4,143শেষ তারিখ
Jan 1, 2027মার্কেট ওপেন হয়েছে
Jun 22, 2026, 10:10 PM ETরেজলভার
0x65070BE91...This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.The FDA's April 2026 withdrawal of BPC-157 from Category 2 removed an explicit enforcement restriction but left the peptide without authorization for routine 503A compounding, as it is neither an approved drug nor on the official bulks list. In July 2026 the Pharmacy Compounding Advisory Committee voted 8-6 (one abstention) to recommend adding BPC-157 (free base and acetate) to the 503A Bulk Drug Substances List for ulcerative colitis use, despite FDA staff briefing documents citing insufficient human safety and efficacy data and potential immunogenicity risks. This non-binding advisory step does not confer Category 1 status or enforcement discretion; any change requires formal notice-and-comment rulemaking, a process that typically spans eight to twenty-four months. No subsequent FDA action or interim Category 1 placement has been reported as of early September 2026.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
ভলিউম
$4,143শেষ তারিখ
Jan 1, 2027মার্কেট ওপেন হয়েছে
Jun 22, 2026, 10:10 PM ETরেজলভার
0x65070BE91...The FDA's April 2026 withdrawal of BPC-157 from Category 2 removed an explicit enforcement restriction but left the peptide without authorization for routine 503A compounding, as it is neither an approved drug nor on the official bulks list. In July 2026 the Pharmacy Compounding Advisory Committee voted 8-6 (one abstention) to recommend adding BPC-157 (free base and acetate) to the 503A Bulk Drug Substances List for ulcerative colitis use, despite FDA staff briefing documents citing insufficient human safety and efficacy data and potential immunogenicity risks. This non-binding advisory step does not confer Category 1 status or enforcement discretion; any change requires formal notice-and-comment rulemaking, a process that typically spans eight to twenty-four months. No subsequent FDA action or interim Category 1 placement has been reported as of early September 2026.
Polymarket ডেটা রেফারেন্স করে পরীক্ষামূলক AI-জেনারেটেড সারাংশ। এটি ট্রেডিং পরামর্শ নয় এবং এই মার্কেট কীভাবে রেজলভ হয় তাতে কোনো ভূমিকা রাখে না। · আপডেটেড
বাহ্যিক লিংক থেকে সাবধান।
বাহ্যিক লিংক থেকে সাবধান।
সচরাচর জিজ্ঞাসা